Paradigm Biopharmaceuticals has reported positive real-world evidence (RWE) of its injectable pentosan polysulfate (iPPS), an antithrombotic agent, in 205 patients suffering from knee osteoarthritis (OA).

Data showed a more than 50% decrease in pain across all the patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company noted that the latest results from 22 patients along with those from the initial 183 subjects brings the average decrease in pain scores to 51.3% across the total 205 patients.

Findings from the additional 22 patients demonstrated sustained average knee pain reduction.

Of the total patients, 89.7% experienced a reduction in joint pain and 91.2% had an improvement in knee function.

In addition, pain scores were found to have decreased by more than 51.3%, while the function was improved on an average of 58.4% from baseline pain scores in 205 participants with knee osteoarthritis (OA) and concurrent bone marrow lesions (BML).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has also obtained RWE of patients with osteoarthritis of other joints such as the hip, ankle and hands. These data are expected to be available in the fourth quarter of CY2019.

Paradigm Biopharmaceuticals CEO Paul Rennie said: “Our strategy of obtaining real-world evidence as we prepare our FDA IND submission for our Phase III OA trial will provide valuable data on our newly manufactured Phase III trial product and will assist in fine-tuning our Phase III trial design.”

Last month, the company reported that a Phase IIb study of iPPS for treating osteoarthritis of the knee met its key secondary endpoints.

Results showed that the therapeutic led to improved knee function and pain reduction, along with a decrease in bone marrow lesion grade, volume and area.